Sun Pharma Can't Quell Patent Feud Over Epilepsy Drug

Law360, Los Angeles (October 7, 2013, 8:29 PM EDT) -- A New Jersey federal judge on Monday refused to dismiss claims against Sun Pharmaceuticals Ltd. in a patent suit over Sun’s generic version of Cephalon Inc.'s anti-epilepsy drug, holding that Cephalon’s complaint sufficiently claims willful infringement.

The decision comes after U.S. District Judge Freda L. Wolfson in December declined to block sales of Sun’s version of tiagabine hydrochloride, marketed as Gabitril, saying Cephalon had failed to prove infringement and raising questions about the patent's validity. Cephalon sued Sun in 2011, claiming Sun had infringed its patent...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.